Partnership / Collaboration · Latin America · Announced 9 Nov 2026

AMA Medical Manufacturing → Barbados Pharmaceutical

Nigeria's AMA Medical Manufacturing signed an MoU with Barbados Pharmaceutical Inc. for a $32 million IV-fluids plant in Barbados with 12 million units a year of initial capacity, targeted to start production in 2029.

Parties: AMA Medical Manufacturing (Nigeria) → Barbados Pharmaceutical Inc. (Barbados)

Value
See terms
Territory
Barbados, serving Caribbean markets
Therapeutic area
Other
Asset
IV fluids
Announced
9 Nov 2026

Our analysis

Why this matters

AMA Medical Manufacturing of Nigeria and Barbados Pharmaceutical Inc. (BPI) signed a memorandum of understanding to develop an intravenous-fluids manufacturing facility in Barbados, reported on 9 November 2026. The agreements were signed on the sidelines of the 2026 Commonwealth Heads of Government Meeting in Antigua and Barbuda, backed by the governments of Nigeria and Barbados. The project is reported at $32 million, with initial capacity of 12 million units a year and production targeted for 2029.

AMA already supplies the Caribbean: its first IV-fluid shipment reached Barbados in March 2026, with further shipments planned for Antigua and Barbuda, the British Virgin Islands and Saint Lucia. Barbados passed legislation in June 2026 creating the Barbados Medical Products Authority.

The full analysis is free to read with a work email on this page.

Source: Leadership (via AllAfrica)

More deals involving AMA Medical Manufacturing or Barbados Pharmaceutical

Latest deals

All Latin America deals → · All partnership / collaboration deals → · Browse all emerging-market pharma deals →